1 Title: Virological evidence of the impact of non-pharmaceutical interventions

2 against COVID-19 in a resource-limited setting

- 3 Andres Moreira-Soto^{1,2}, Alfredo Bruno^{3,4}, Doménica de Mora³, Michelle Paez³, Jimmy
- 4 Garces³, Ben Wulf¹, Anna-Lena Sander¹, Maritza Olmedo³, Maria José Basantes Mantilla³,
- 5 Manuel Gonzalez^{3,5}, Alberto Orlando Nárvaez^{3,4}, Silvia Salgado³, Juan Carlos Zevallos^{6,7},
- 6 Jan Felix Drexler^{1,8*}
- 7

8 Affiliations:

- 9 ¹Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt
- 10 Universität zu Berlin, Institute of Virology, Berlin, Germany.
- ¹¹ ²CIET, Faculty of Microbiology, University of Costa Rica, San José, Costa Rica
- ¹² ³National Institute of Public Health Research (INSPI), Guayaquil, Ecuador
- ⁴ Universidad Agraria del Ecuador, Guayaquil, Guayas, Ecuador
- ⁵Guayaquil University, Guayaquil, Guayas, Ecuador
- ⁶ Health Science Faculty, Universidad Espíritu Santo, Guayaquil, Ecuador (UEES).
- ¹⁶ ⁷Alianza para la Investigación de Enfermedades Emergentes (AIE), Quito, Ecuador.
- ¹⁷ ⁸German Centre for Infection Research (DZIF), associated partner site Charité, Berlin, Germany
- 18
- 19 Correspondence:
- ²⁰ *Jan Felix Drexler, ¹Charité-Universitätsmedizin Berlin, Institute of Virology, Charitéplatz 1,
- 21 10098 Berlin, Germany. Email: felix.drexler@charite.de
- 22

23 Abstract:

Ecuador was an early COVID-19 hotspot with substantial COVID-19-mortality. In developed countries, low socioeconomic status is associated with COVID-19 infection and low compliance with non-pharmaceutical interventions (NPIs). However, if NPI were successful in resourcelimited settings with high human mobility and informal labour is still unclear. We performed a retrospective observational molecular and serological study of Ecuador's reference laboratory. We tested 1,950 respiratory samples from COVID-19 surveillance for SARS-CoV-2 and 12

respiratory viruses using RT-PCR, characterized 642 SARS-CoV-2 genomes, and examined
 SARS-CoV-2 seroprevalence in 1,967 samples from patients with fever in Ecuador's reference
 laboratory during 2020-2021. Molecular and serological data were compared to NPI stringency
 in Bayesian, maximum-likelihood and modelling frameworks.

SARS-CoV-2 (Pearson correlation test; r=-0.74; p=0.01) and other respiratory viruses (r=-0.68; 34 p=0.02) detection correlated negatively with NPI stringency. SARS-CoV-2 seroprevalence 35 increased from <1% during February-March 2020 to 50% within 6 weeks and plateaued after 36 NPI implementation. Decrease of effective reproduction number <1 and antibody reactivity over 37 time suggested intense SARS-CoV-2 transmission during pandemic onset, subsequently limited 38 by NPIs. Phylogeographic analyses revealed that travel restrictions were implemented late not 39 preventing 100 near-parallel SARS-CoV-2 introductions, and implementation of NPIs modified 40 SARS-CoV-2 geographic spread by restricting recreational activity. NPIs stringency correlated 41 negatively with the number of circulating SARS-CoV-2 lineages (r=-0.69; p=0.02). Virological 42 evidence supports NPIs restricting human movement as an effective public health tool to control 43 the spread of respiratory pathogens in resource-limited settings, providing a template for 44 45 emerging SARS-CoV-2 variants and future epidemics.

46

47 **INTRODUCTION**

Latin America is a COVID-19 hot spot, accumulating 20% of reported cases and 32% of deaths 48 49 worldwide in 2020¹, albeit hosting only 8% of the total world's population. Latin America suffered substantial economic constrains due to the pandemic, exemplified by the decline of 50 9.4% 51 in gross domestic product in 2020 (https://www.imf.org/en/Publications/WEO/Issues/2020/06/24/WEOUpdateJune2020). Most of 52 the economic constraints were associated with compulsory non-pharmaceutical interventions 53 54 (NPIs), i.e., policies that restrict human contact, movement, and shut down public and private services to avoid SARS-CoV-2 transmission. However, resource-limited settings such as Latin 55 America have very high proportions of informal labour reaching more than 80% (International 56 Labour Organization; https://ilostat.ilo.org/data/), involving high human mobility that may put 57 the efficacy of NPIs at stake. Even in affluent settings, the efficacy of NPIs in containing 58 COVID-19 mortality and SARS-CoV-2 spread is debated. On the one hand, early research in 59 China and Brazil suggested that NPIs decreased SARS-CoV-2 transmission rates² and 60

reproduction number³, and a time series meta-analysis of 149 countries showed a decrease of COVID-19 incidence rates by 13% after NPI implementation⁴. On the other hand, a modelling study analysing European countries found no efficacy of relatively less stringent NPIs in lowering SARS-CoV-2 transmission apart from a complete lockdown⁵, and another study in Europe found that closure of businesses and stay-at-home orders were unlikely to lower COVID-19 incidence⁶.

To date, analyses of the COVID-19 public health response relied predominantly on surveillance 67 data, leading to inevitable biases due to the limited diagnostic testing and underreporting in 68 resource-limited settings. These biases have been partially resolved using reported excess deaths, 69 but those data are not immediately available and depend on the quality of national data registers 70 71 ⁷. Within Latin America, Ecuador was one of the earliest epicentres of the pandemic, with one of the highest COVID-19-associated mortality rates worldwide reaching 8.5% in late 2020⁷ and an 72 80% increase in excess deaths of baseline annual mortality⁷ despite strict and early NPI 73 implementation. Here, we use virological data to analyse the efficacy of NPIs in Ecuador, a 74 prototypic resource-limited setting in Latin America. 75

76

77 MATERIALS AND METHODS

Study design: Patient samples originated mainly from coastal Ecuador, separated from the rest 78 of the country by the Andean mountains and home to most of the Ecuadorian population (Fig. 79 1A) (further geographical data shown in Fig. S1). That region of Ecuador was chosen because it 80 was most affected by COVID-19 during the onset of the pandemic and because it harbours the 81 Ecuadorian SARS-CoV-2 reference laboratory the Instituto Nacional de Investigación en Salud 82 83 Pública Dr. Leopoldo Izquieta Pérez (INSPI). Other regions of Ecuador have separate and smaller reference laboratories and samples from those laboratories were hardly available for this 84 study. We used two different subpopulations collected retrospectively from routine disease 85 surveillance from the Ecuadorian National surveillance system (Fig. 1B and 1C). First, we 86 performed a molecular study using 1950 oro-nasopharyngeal swabs and sputum samples sent for 87 routine SARS-CoV-2 surveillance to INSPI during March 2020 to February 2021, corresponding 88 to 2.3% of all the samples analysed by the INSPI per week (Fig. 1B; further subsample data is 89 found in Fig. S1, S2, S3 and S4, and in Table S1). Second, all available samples of fever of 90 unknown origin (FUO) sent to INSPI from January 2020 to February 2021 for medical 91

92 investigation were used to measure SARS-CoV-2 antibodies (Fig. 1C; sub-population characteristics are shown in Table S2 and Fig. S5 and S6). Both subpopulations correspond to 93 94 longitudinal collections of diagnostic samples spanning comparable timeframes, number of samples and geographical location (Fig. 1D and 1E). Sample numbers per province were 95 comparable between both subpopulations, and only 12% (n=243/1967) of the FUO samples were 96 from provinces outside of coastal Ecuador from which no respiratory samples were available 97 (Fig. 1D and 1E). Although the subpopulation with FUO was younger than the subpopulation 98 with respiratory illness, those samples are independently suitable to describe the sample 99 reception and surveillance performed in the national reference laboratory of Ecuador during the 100 onset of the pandemic (Fig. S2 through S6). 101

102

Laboratory analyses: Molecular testing for SARS-CoV-2 and common respiratory viruses (four 103 endemic human coronaviruses (HCoV)-OC43, -NL63, -229E, -HKU1; Human adenoviruses, 104 metapneumovirus, parechovirus, influenza A/B virus, respiratory syncytial viruses A/B, 105 enteroviruses and parainfluenza viruses 1-4) was done using commercially available multiplex 106 real-time RT-PCR kits, SARS-CoV-2 whole-genome amplification and assembly using readily 107 (https://gitlab.com/RKIBioinformaticsPipelines/ncov minipipe) available 108 pipelines and classification using (PANGOLIN) version 3.1.16⁸. Serological testing included a validated 109 SARS-CoV-2 testing algorithm based on a chemiluminescence immunoassay followed by a 110 highly specific SARS-CoV-2 surrogate virus neutralization test described before⁹. 111

112

Evolutionary analyses: We constructed an approximately-maximum likelihood (ML) phylogeny encompassing all SARS-CoV-2 sequences from this study and all available GISAID genomes until September 1, 2021 using the program fasttree 2.1.10¹⁰ with a GTR+CAT substitution model. To explore the temporal signal of SARS-CoV-2, an ancestral state inference in an ML framework was calculated in TreeTime 0.7.6¹¹. Phylogeographic inference was calculated using the relaxed random walk (RRW) diffusion model run for $1 \square \times \square 10^8$ generations implemented in BEAST v1.10.4.

121 Statistical analyses and modelling: Chi-square tests of proportions and Fisher's exact tests were used to compare categorical variables, t-tests and Pearson correlation tests to compare 122 123 continuous variables using R (v. 4.0.3). Kernel density estimations (KDE), used to visualize the distribution of continuous variables in time were performed in R (v. 4.0.3). KDE were calculated 124 using the smallest bandwidth possible due to our large sample size. COVID-19 outbreak 125 dynamics were analysed using a susceptible-exposed-infectious-recovered (SEIR) model 126 modified to fit COVID-19 estimates¹². Further details on materials and methods are found in the 127 Supplementary text. 128

129

130 **RESULTS**

131 NPI implementation in Ecuador

Ecuador's public health response to COVID-19 started immediately after declaration of the 132 pandemic by the WHO on March 11, 2020^{13} . Ecuador's government implemented an emergency 133 state, handing pandemic response to the central government. The implemented NPIs increased in 134 severity and included closing of national borders on March 16, followed by banning social 135 gatherings, a curfew, closing of public spaces, commerce, schools, and stay-at-home orders by 136 March 23, corresponding to a high NPI stringency level of 93% according to the widely used 137 Oxford-based classification system¹⁴. The Stringency index is calculated as the mean score of 138 nine metrics: school closures; workplace closures; cancellation of public events; restrictions on 139 public gatherings; closures of public transport; stay-at-home requirements; public information 140 campaigns; restrictions on internal movements; and international travel controls. In Ecuador, the 141 NPI stringency index decreased 3-7% per month until mid-September 2020, time in which 142 Ecuador central government lifted stay-at-home orders, travel restrictions, permitted public 143 gatherings, and gave political power to local governments to decide on NPIs. Afterwards, the 144 stringency index was approximately 50% for the rest of the year (stringency of NPI over time is 145 shown in Fig. S10). Of note, the obligatory use of masks in indoor and outdoor spaces was 146 implemented on April 6, 2020 and lifted on April 2022. 147

148

149 NPIs likely constrained circulation of SARS-CoV-2 and other respiratory viruses

During the onset of the pandemic, Ecuador's laboratory testing capacity was below all other South American countries, reaching 40 tests per 1000 inhabitants as of December, 2020^{1} , and

152 lack of reagents challenged homogenous testing over time (total number of tests shown in grey in Fig. 2A) (https://www.theguardian.com/world/live/2020/jun/12/coronavirus-live-news-markets-153 154 fall-over-fears-of-long-us-recovery-as-brazil-cases-top-800000). Therefore, we re-tested 1,950 samples stored at Ecuador's reference laboratory continuously during the first year of the 155 COVID-19 pandemic (mean, 47.8 samples per week (range: 27.5 to 60). In total, 52% 156 (1017/1950) of those samples were SARS-CoV-2 positive. The high RT-PCR detection rate is 157 consistent with the Ecuadorian testing algorithm focusing on symptomatic cases and contacts¹⁵. 158 The SARS-CoV-2 RT-PCR detection per month correlated significantly with lower stringency of 159 NPIs, implying increased virus circulation before NPIs were implemented and after NPIs were 160 relaxed (Pearson correlation test; r=-0.74; p=0.01) (Fig. 2B). The positivity rate decreased 161 slowly with time, from 40% in March 2020, when the more stringent NPIs were implemented, 162 until 20% in September 2020, were NPIs were the lowest, suggesting that NPIs were successful 163 in controlling virus spread. As soon as NPI stringency was lowered, the positivity rate got a steep 164 increase reaching close to 40% during late 2020, following the reported excess mortality increase 165 (**Fig.** 2A). 166

The overall detection rate of all other respiratory viruses was low at 4.7% (91/1950; CI: 3.9-5.8) 167 (Fig. 2C). Among common respiratory viruses, adenoviruses (Fisher's exact-test; p=0.026), 168 parainfluenzaviruses (Fisher's exact-test; p=0.04), enteroviruses (Fisher's exact-test; p<0.0001) 169 and metapneumoviruses (Fisher's exact-test; p < 0.0001) occurred significantly more frequently 170 171 during months of non-stringent NPIs, being the odds of detecting respiratory viruses 2-23 times higher in lower NPI as in stringent NPIs times (individual detection of respiratory viruses in 172 SARS-CoV-2-positive and -negative patients are shown in Fig. S13). Similar to SARS-CoV-2, 173 the detection of those common respiratory viruses significantly correlated with less stringent 174 175 NPIs (Pearson correlation test; r=-0.68; p=0.02) (Fig. 2C), reminiscent of the reduced circulation of SARS-CoV-2 and suggesting modified respiratory virus circulation according to NPI 176 stringency. Therefore, there was reduced respiratory virus circulation in comparison to pre-177 pandemic detection rates in Ecuador¹⁶. Co-infection between SARS-CoV-2 and other respiratory 178 179 viruses was detected in 4.4% of SARS-CoV-2 positive samples (44/1017; CI: 6.1-9.4), and only in one other sample by non-SARS-CoV-2 respiratory viruses (Fig. S13). The detected rates of 180 co-infection were considerably lower than co-infection rates found in pre-pandemic studies from 181 tropical settings, reaching more than 10% using similar methodology¹⁷. Overall decreased virus 182

circulation was likely associated with stringent NPIs and included the complete absence of influenza viruses, consistent with a study from the United Kingdom¹⁸. Finally, co-infections did

- not affect COVID-19 severity or duration (data on disease outcome are found in **Fig. S14**).
- 186

187 SARS-CoV-2 seroprevalence plateaued following the implementation of NPIs

SARS-CoV-2-specific IgG antibodies were first detected during late March 2020 (Fig. 3A). IgG 188 seroconversion occurs in patients approximately after the third week of illness¹⁹. Therefore, the 189 serological data was in concordance with the first SARS-CoV-2 case detected in the country on 190 February 29th. One month later, during early May 2020, SARS-CoV-2 seroprevalence reached 191 50% and stagnated afterwards (Fig. 3A), compatible with intense SARS-CoV-2 transmission 192 during the onset of the pandemic mainly in coastal Ecuador, followed by limited onward 193 transmission due to NPIs (Fig. S7, S8 and S9). This interpretation was consistent with decreasing 194 levels of antibodies over time in our dataset (Fig. 3B; Fig. S7) and the modelled effective 195 reproduction number (R_{eff}) <1 using seroprevalence and incidence data, during stringent NPIs 196 (Fig. 3C), and reminiscent of an observational study showing decreased SARS-CoV-2 197 circulation due to implementation of NPIs in Hong Kong²⁰ and a modelled decrease of R_{eff} 198 estimates due to NPIs from São Paulo and Rio de Janeiro, Brazil during the onset of the 199 pandemic³. Given the relatively young age of patients in this subpopulation, the overall 200 seroprevalence in Ecuador may be under or overestimated. However, comparable seroprevalence 201 202 estimates in a population-based study from Peru showed an equal seroprevalence distribution amongst age groups²¹. From September 2020 onwards, R_{eff} re-increased >1, and from December 203 2020 onwards, mean CLIA antibody reactivity levels re-increased, likely due to relaxed NPIs 204 leading to increased virus transmission (Fig. 3C and Fig. S7). 205

206

Travel restrictions were implemented too late to prevent parallel SARS-CoV-2 introductions

Since there is a lack of SARS-CoV-2 genomic data from the onset of the COVID-19 pandemic in Ecuador²², we sequenced 63.1% (642/1017) of the SARS-CoV-2-positive samples. Phylogenomic reconstructions combining our new data and all SARS-CoV-2 sequences from Ecuador in GISAID until September 2021 revealed that SARS-CoV-2 was introduced into Ecuador between February 17 to March 8, 2020 (**Fig. 4A**). The time of introduction was similar

to estimates from Brazil, the first country in Latin America detecting SARS-CoV-2³, and thus 214 compatible with early spread of COVID-19 in Ecuador and robustness of our data. That time 215 216 span also included the first reported case of SARS-CoV-2 infection from Ecuador and was in concordance with our serological data, again suggesting robustness of our results. Close to 100 217 separate SARS-CoV-2 introduction events into Ecuador were suggested by the low average 218 genetic divergence, the similar detection time and the clustering of the early SARS-CoV-2 219 viruses in the time stamped tree in early SARS-CoV-2 sequences from Ecuador (Fig. 4A; see 220 divergence data in Fig. S15 and S16). Although Ecuador was among the first Latin American 221 countries to implement travel restrictions by March 16, 2020, those NPIs were apparently 222 implemented too late to prevent multiple parallel introduction events. For comparison, similarly 223 high numbers of parallel SARS-CoV-2 introductions were reported during the onset of COVID-224 19 in Brazil, again suggesting robustness and generalizability of our data³. 225

226

227 NPI implementation slowed the emergence of new SARS-CoV-2 lineages

The SARS-CoV-2 strains circulating in Ecuador during 2020 and 2021 were assigned to 66 228 229 different lineages (see distribution of Pango lineages over time in Fig. S17 and S18). The early phase of the pandemic in Ecuador was characterized by the predominance of lineages B.1, B.1.1 230 and its sub-lineages; B.1.1 representing 30% of the total genomic data. Both B.1 and B.1.1. 231 lineages were detected during February 2020 in Europe and to a lesser extent in North America 232 and Asia²³, and in Ecuador during March 2020, again compatible with travel-aided SARS-CoV-233 2 introduction events into Ecuador. In our dataset, a mean of 7.6 (range: 4-13; CI: 4.4-10.8) 234 235 SARS-CoV-2 Pango lineages were detected during March to August 2020. Once NPIs were relaxed from September to December 2020, almost twice as many lineages circulated despite the 236 237 shorter time span (mean, 16; range: 11-19; CI: 10.4-21.6) (Fig. 4B). Moreover, the number of lineages was negatively correlated with the stringency of NPIs, suggesting accelerated viral 238 evolution due to increased transmission and introduction of previously non-endemic lineages 239 once NPIs were relaxed (**Fig. 4C**) (Pearson correlation test; (r=-0.69; p=0.02). 240

241

242 NPIs modified the dispersion of SARS-CoV-2

243 Phylogeographic reconstructions of the regionally predominant SARS-CoV-2 lineage B.1.1 244 showed differential dispersion patterns during different phases of the pandemic. At the onset of

the pandemic, geographic transitions originated unidirectionally from coastal Ecuador to other 245 provinces (Fig. 4D), which was in concordance to our time-stamped analyses, and in 246 247 concordance to the natural progression of SARS-CoV-2 geographic spread. Two weeks after the implementation of strict NPIs, a 54% decrease of geographic transitions entailed, followed by 248 continuously low numbers of geographic transitions (Fig. 4D and 4E). Virus movements during 249 strict NPIs occurred multidirectionally over relatively larger distances (Fig. 4D), potentially due 250 251 to increased mobility associated with commercial reactivation during mid-2020 in all of South America²⁴, since travel restrictions and stay-at-home orders were still implemented. Once NPIs 252 were relaxed, transitions peaked again and occurred predominantly over shorter distances, 253 potentially associated with recreational activity, as a high number of transitions occurred to and 254 from coastal provinces (Fig. 4D and 4E). 255

256

257 **DISCUSSION**

We gathered virological data describing the onset of the COVID-19 pandemic in a Latin 258 American COVID-19 epicentre to show that NPIs were a modifying and limiting factor of 259 SARS-CoV-2 transmission. NPIs are a well-known part of public health responses to epidemics 260 and have been used, among others, during the SARS-CoV epidemic in 2003 and the Spanish flu 261 in 1918. However, the success of NPIs in containing outbreaks varied depending on several 262 factors, including region, time of implementation, cultural background of the population, its prior 263 experience to epidemics and civil compliance to the imposed restrictions ^{25,26}. For SARS-CoV-2, 264 a comparative study analysing public health responses in developed and a limited number of 265 developing countries suggested that the success of NPIs depended on governmental monitoring 266 and early and stringent application of NPIs²⁷, which are particularly difficult in resource-limited 267 settings such as Latin America due to several factors. First, testing of SARS-CoV-2 in Latin 268 America is insufficient and assessments of base mortality are often delayed ⁷. Second, 269 monitoring and implementation of NPIs is complicated in rural settings, in which circa 20% of 270 Latin American populations reside ⁹ and in which access to healthcare services is limited and 271 COVID-19 stigmatization, i.e. delay of seeking care due to negative economic or social 272 consequences, is frequent ^{9,28}. Third, compliance with NPIs by the population is affected by 273 socio-demographic characteristics such as poverty and ethnicity ²⁹ and Latin American societies 274 are prototypic examples of resource-limited multi-ethnic settings. Fourth and potentially most 275

importantly, informal labor reaches more than 60% of workforce in Ecuador and other parts of 276 Latin America³⁰, and stay-at-home orders cannot be followed by persons relying on daily 277 278 informal income and lacking infrastructure to store food. Those factors may explain why despite strict NPIs, the death toll continued to rise in Ecuador and other regions of Latin America, and 279 why Latin America is a priority region for rapid vaccination ³¹. Whether NPIs were thus a 280 meaningful tool to contain COVID-19 in Latin America and whether the socio-economic costs of 281 NPIs were justified thus remained unclear ³². In stark contrast, our data reveal an impact of NPIs 282 on all aspects of SARS-CoV-2 epidemiology and strongly suggest that without NPIs, the death 283 toll would have been much higher during the first year of the pandemic in Latin America, 284 reminiscent of a retrospective modelling study on NPI implementation in 2020 in India, which 285 projected a 60% reduction in deaths compared to non-implementation of NPIs³³. 286

287

288 Limitations

Limitations of our study include the use of serum and respiratory samples that were not designed 289 to represent Ecuador's population and that we assume no reduction in compliance over time of 290 NPIs, which are less followed by persons with low socioeconomic status ³⁴. Additionally, the use 291 of the Oxford stringency index summarizing NPIs considers measures isolated from regional 292 contexts, such as informal labour proportion and the degree of enforcement of NPIs by regional 293 authorities. However, using policy response aggregates might be of use because individual 294 295 policies during the first pandemic year had limited variation across and within countries, resulting in collinear relationships ¹⁴. Another limitation are the intrinsic biases of phylogenetic 296 analyses due to representability of spatiotemporal samples and the lack of a bigger genomic 297 dataset from Ecuador in comparison to other Latin American countries such as Brazil ³. 298 299 However, our samples are representative of the Ecuadorian national testing algorithm and taken at even rates continuously across the first year of the COVID-19 pandemic and should thus allow 300 robust interpretations despite inevitable sample biases, consistent with similar detection patterns 301 of SARS-CoV-2 and other respiratory viruses. Phylogenomic analyses from an affluent setting 302 confirmed usability of genomic data to analyse NPI efficacy ³⁵. Additionally, acute febrile 303 disease from arbovirus infections or malaria is common in poorer population strata¹² and those 304 sera should allow sensitive detection of past SARS-CoV-2 infection which is also common in 305 poorer population strata³⁶. 306

307

Methodological strengths of our study include the use of exhaustive molecular, phylogenetic, modelling and serological analyses whose results mutually confirmed each other and compensate for the study's inherent limitations.

311

312 Conclusion

Our data support that stringent NPIs modifying human behaviour, e.g., limiting human 313 movement, social gatherings and increasing available information to the public were efficient 314 against COVID-19 in Ecuador, but intense SARS-CoV-2 spread occurred before their 315 implementation. Therefore, NPIs should be rapidly implemented and sustained in 316 immunologically naïve populations upon introduction of a highly transmissible pathogen such as 317 SARS-CoV-2. This interpretation is in concordance with studies showing increased mortality 318 when NPIs were introduced too late and lifted too early during the 1918 Spanish flu pandemic in 319 the U.S.²⁶ and from early travel restrictions globally reducing case numbers during the onset of 320 the COVID-19 pandemic ³⁷. Finally, the emergence of antigenically distinct SARS-CoV-2 321 variants worldwide ³⁸ leading to decreased vaccine effectiveness ³⁹, together with the delayed 322 modification of vaccines worldwide has led countries such as China, Canada and Peru to 323 implement similarly stringent NPIs as in 2020, affecting hundreds of millions of people in 2022. 324 Overall, our analyses of virological data provide an evidence-based way to justify the 325 326 implementation of NPIs, providing data-driven support to stakeholders facing resurge of SARS-CoV-2 immune escape variants or future epidemics globally. Nonetheless, the virological benefit 327 of NPIs must be weighed against the capacities of public health systems in managing severe 328 COVID-19 cases, e.g. intensive care units, respirators, and oxygen, all limited in resource-329 limited settings like Latin America ^{40,41} and the high societal ⁴² and economic costs associated 330 with NPIs. 331

332

333 **References**

 Roser, M. Coronavirus Pandemic (COVID-19). *Our World in Data* (2020).
 Hou, C., *et al.* The effectiveness of quarantine of Wuhan city against the Corona Virus Disease 2019 (COVID-19): A well-mixed SEIR model analysis. *J Med Virol* 92, 841-848 (2020).

3. Candido, D.S., et al. Evolution and epidemic spread of SARS-CoV-2 in Brazil. Science 338 339 369, 1255-1260 (2020). 4. Islam, N., et al. Physical distancing interventions and incidence of coronavirus disease 340 341 2019: natural experiment in 149 countries. BMJ 370, m2743 (2020). Flaxman, S., et al. Estimating the effects of non-pharmaceutical interventions on 5. 342 COVID-19 in Europe. Nature 584, 257-261 (2020). 343 6. Hunter, P.R., Colon-Gonzalez, F.J., Brainard, J. & Rushton, S. Impact of non-344 pharmaceutical interventions against COVID-19 in Europe in 2020: a quasi-experimental 345 non-equivalent group and time series design study. Euro Surveill 26(2021). 346 7. Cuellar, L., et al. Excess deaths reveal the true spatial, temporal and demographic impact 347 of COVID-19 on mortality in Ecuador. International journal of epidemiology (2021). 348 8. Rambaut, A., et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist 349 genomic epidemiology. Nature Microbiology 5, 1403-1407 (2020). 350 9. Moreira-Soto, A., et al. High SARS-CoV-2 Seroprevalence in Rural Peru, 2021: a Cross-351 Sectional Population-Based Study. *mSphere* 6, e0068521 (2021). 352 10. Price, M.N., Dehal, P.S. & Arkin, A.P. FastTree 2--approximately maximum-likelihood 353 354 trees for large alignments. PLoS One 5, e9490 (2010). Sagulenko, P., Puller, V. & Neher, R.A. TreeTime: Maximum-likelihood phylodynamic 11. 355 analysis. Virus Evol 4, vex042 (2018). 356 Netto, E.M., et al. High Zika Virus Seroprevalence in Salvador, Northeastern Brazil 357 12. Limits the Potential for Further Outbreaks. *mBio* 8(2017). 358 13. Garcia, P.J., et al. COVID-19 Response in Latin America. Am J Trop Med Hyg 103, 359 1765-1772 (2020). 360 14. Hale, T., et al. A global panel database of pandemic policies (Oxford COVID-19 361 Government Response Tracker). Nat Hum Behav 5, 529-538 (2021). 362 15. Cañizares Fuentes, R., Aroca, R. & Blasco Carlos, M. Evaluation of COVID-19 363 Surveillance Strategy in Ecuador. Disaster Medicine and Public Health Preparedness, 1-364 4 (2020). 365 16. Caini, S., et al. The epidemiology and severity of respiratory viral infections in a tropical 366 country: Ecuador, 2009-2016. J Infect Public Health 12, 357-363 (2019). 367 Góes, L.G.B., et al. Typical epidemiology of respiratory virus infections in a Brazilian 17. 368 slum. J Med Virol 92, 1316-1321 (2020). 369 Poole, S., Brendish, N.J. & Clark, T.W. SARS-CoV-2 has displaced other seasonal 370 18. respiratory viruses: Results from a prospective cohort study. J Infect 81, 966-972 (2020). 371 19. To, K.K., *et al.* Temporal profiles of viral load in posterior oropharyngeal saliva samples 372 and serum antibody responses during infection by SARS-CoV-2: an observational cohort 373 study. Lancet Infect Dis 20, 565-574 (2020). 374 20. Cowling, B.J., et al. Impact assessment of non-pharmaceutical interventions against 375 coronavirus disease 2019 and influenza in Hong Kong: an observational study. Lancet 376 Public Health 5, e279-e288 (2020). 377 21. Reyes-Vega, M.F., et al. SARS-CoV-2 prevalence associated to low socioeconomic 378 status and overcrowding in an LMIC megacity: A population-based seroepidemiological 379 survey in Lima, Peru. EClinicalMedicine 34, 100801 (2021). 380 22. Gutierrez, B., et al. Genomic epidemiology of SARS-CoV-2 transmission lineages in 381 382 Ecuador. medRxiv (2021).

383	23.	Alteri, C., et al. Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and
384		early spread of SARS-CoV-2 infections in Lombardy, Italy. Nat Commun 12, 434 (2021).
385	24.	van Ruitenbeek, R.E., Slik, J.S. & Bhulai, S. On the relation between COVID-19,
386		mobility, and the stock market. PLoS One 16, e0261381 (2021).
387	25.	Matthews Pillemer, F., Blendon, R.J., Zaslavsky, A.M. & Lee, B.Y. Predicting support
388		for non-pharmaceutical interventions during infectious outbreaks: a four region analysis.
389		Disasters 39 , 125-145 (2015).
390	26.	Bootsma, M.C. & Ferguson, N.M. The effect of public health measures on the 1918
391		influenza pandemic in U.S. cities. Proc Natl Acad Sci U S A 104, 7588-7593 (2007).
392	27.	Xylogiannopoulos, K.F., Karampelas, P. & Alhajj, R. COVID-19 pandemic spread
393		against countries' non-pharmaceutical interventions responses: a data-mining driven
394		comparative study. BMC Public Health 21, 1607 (2021).
395	28.	McDermott, J.H. & Newman, W.G. Refusal of viral testing during the SARS-CoV-2
396		pandemic. Clin Med (Lond) 20, e163-e164 (2020).
397	29.	Pan, W.K., et al. Heterogeneity in the Effectiveness of Non-pharmaceutical Interventions
398		During the First SARS-CoV2 Wave in the United States. Front Public Health 9, 754696
399		(2021).
400	30.	Canelas, C. Informality and poverty in Ecuador. Small Business Economics 53, 1097-
401		1115 (2019).
402	31.	Bollyky, T.J., Murray, C.J.L. & Reiner, R.C., Jr. Epidemiology, not geopolitics, should
403		guide COVID-19 vaccine donations. <i>Lancet</i> 398 , 97-99 (2021).
404	32.	Knaul, F.M., et al. Punt Politics as Failure of Health System Stewardship: Evidence from
405		the COVID-19 Pandemic Response in Brazil and Mexico. Lancet Reg Health Am 4,
406		100086 (2021).
407	33.	Salvatore, M., et al. Lessons from SARS-CoV-2 in India: A data-driven framework for
408		pandemic resilience. Science Advances 8, eabp8621.
409	34.	de Noronha, N., et al. Non-adherence to COVID-19 lockdown: who are they? A cross-
410		sectional study in Portugal. Public Health 211, 5-13 (2022).
411	35.	Nadeau, S.A., et al. Swiss public health measures associated with reduced SARS-CoV-2
412		transmission using genome data. Sci Transl Med 14, eabn7979 (2022).
413	36.	Reves-Vega, M.F., et al. SARS-CoV-2 prevalence associated to low socioeconomic
414		status and overcrowding in an LMIC megacity: A population-based seroepidemiological
415		survey in Lima, Peru. EClinicalMedicine 34, 100801 (2021).
416	37.	Grépin, K.A., et al. Evidence of the effectiveness of travel-related measures during the
417		early phase of the COVID-19 pandemic: a rapid systematic review. BMJ Global Health
418		6 , e004537 (2021).
419	38.	Yewdell, J.W. Antigenic drift: Understanding COVID-19. Immunity 54, 2681-2687
420		(2021).
421	39.	Andrews, N., et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529)
422		Variant. N Engl J Med 386 , 1532-1546 (2022).
423	40.	Benítez, M.A., et al. Responses to COVID-19 in five Latin American countries. Health
424		<i>Policy and Technology</i> 9 , 525-559 (2020).
425	41.	Reperant, L.A. & Osterhaus, A. COVID-19 vaccination and critical care capacity:
426		Perilous months ahead. Vaccine 39 , 2183-2186 (2021).

427 42. Lichand, G., Doria, C.A., Leal-Neto, O. & Fernandes, J.P.C. The impacts of remote
428 learning in secondary education during the pandemic in Brazil. *Nat Hum Behav* 6, 1079429 1086 (2022).

431

Acknowledgments: We thank Arne Kühne for technical support. We thank Carlo Fischer for the
 critical reading of the manuscript.

Funding: This work was supported German Federal Ministry for Economic Cooperation and
Development (BMZ) through the Deutsche Gesellschaft für Internationale Zusammenarbeit
(GIZ) to JFD (project number 81272349).

437

Ethical statement: All patient data were managed in anonymized databases by the INSPI.
Clinical symptoms were retrieved from medical charts. The study was approved by the
Ecuadorian Ministry of Health (MSP-MSP-2021-0006-O-FDQ) and the Ethics committee of the
Espiritu Santo University in Guayaquil, Ecuador (2022-002A).

442

Author contributions: Conceptualization (AM-S, JCZ, JFD), data curation (AB, DdM, MP, 443 JG, JG, BW, A-LS, MO, MJB, MG, AO, SS), formal analysis (AM-S, AB, DdM, MP, JG, BW, 444 A-LS, MO, MJB, MG, AO, SS, JCZ, JFD), funding acquisition (JFD), investigation (AM-S, 445 AB, DdM, MP, JG, BW, A-LS, MO, MJB, MG, AO, SS, JCZ, JFD), methodology (AM-S, AB, 446 DdM, MP, JG, BW, A-LS, MO, MJB, MG, AO, SS, JCZ, JFD), project administration (AM-S, 447 AO, JCZ, JFD), resources (AM-S, AB, DdM, MP, JG, BW, A-LS, MO, MJB, MG, AO, SS, 448 JCZ, JFD), software (AM-S, A-LS, BW), visualization (AM-S, BW, A-LS), writing – original 449 450 draft (AM-S, AB, DdM, MP, JG, BW, A-LS, MO, MJB, MG, AO, SS, JCZ, JFD), and writing -451 review & editing (AM-S, JFD)

452

453 **Competing interests:** Authors declare that they have no competing interests.

Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary materials. The data that is not patient associated will be made available for research on reasonable request and with permission from the INSPI and the Ecuadorian ministry of health. Newly generated SARS-CoV-2 sequences were uploaded

- assembly can be found in ebi.ac.uk under the accession: ERP145042. All the code to reproduce
- the analyses can be found at: https://github.com/Dokandres/EcuadorNPI.

461 **Figures**





Figure 1. Study sites and sample collection. (A) Map of South America, Ecuador is shown in 464 orange. Bottom: Population density map of Ecuador. (B) Subpopulation of SARS-CoV-2 465 surveillance used for the molecular study in Ecuador, time span of sampling, and specimens per 466 subpopulation. Bottom: Spatial distribution of samples. (C) Subpopulation of fever of unknown 467 origin surveillance used for the serological study in Ecuador, time span of sampling, and 468 specimens per subpopulation. Bottom: Spatial distribution of samples. Logarithmic scale was 469 used in (B) and (C) for clarity of presentation. (D) Bivariate map of number of respiratory and 470 fever of unknown origin (FUO) samples in Ecuador. (E) Bar chart showing the number of 471 respiratory samples (left) and serum samples (right) per province. Black corresponds to 472

473provinces were both subpopulations are represented. Gray corresponds to provinces where only474FUO samples were available. Ecuador's political division data (https://www.diva-gis.org/gdata;475https://gadm.org/)andEcuador's476(https://hub.worldpop.org/geodata/summary?id=46031;WorldPopdatasets47710.5250/00TEON/MID20(75)data

- 477 10.5258/SOTON/WP00675) were gathered from freely available sources.
- 478



479 480 Figure 2. Circulation of SARS-CoV-2 and other respiratory viruses in Ecuador. (A)

Reported number of cases and all-cause excess mortality from the Ecuadorian Ministry of Health

482 (<u>www.salud.gob.ec</u>) and positivity rate from Ecuador's reference Laboratory. Above: Total

number of tests per thousand inhabitants (Our World in Data) and Oxford stringency index. (B)

484 Kernel density estimations of SARS-CoV-2 detections. Below: Pearson correlation test of NPI

485 stringency index versus number of SARS-CoV-2 detections per month. (C) Kernel density

estimations of non-SARS-CoV-2 respiratory viruses. Below: Pearson correlation test of NPI

487 stringency index versus number of respiratory virus detections per month. Viruses with less than

488 two detections are not shown for graphical reasons. Human adenoviruses (hAdV),

metapneumovirus (hMPV), enteroviruses (EV) and parainfluenza viruses 1-4 (hPIV 1-4). Epiwk:
Epidemiological week.

491



Figure 3. Seroprevalence and transmission of SARS-CoV-2 in Ecuador. (A) Seroprevalence
per epidemiological week. Right axis denotes kernel density estimation analyses of SARS-CoV2-specific antibodies in Ecuador. (B) CLIA concentration across time in the tested samples. The

black line denotes the mean CLIA concentration per month. Gray lines denote the 95% 497 confidence interval. AU/ml: absorbance units per millilitre. (C) Calculated effective reproduction 498 499 number from seroprevalence estimates and reported cases over time. Epiwk: Epidemiological 500 week.



Figure 4. Evolution and spread of SARS-CoV-2 in Ecuador. (A) Time-resolved maximum 503 clade credibility phylogeny of SARS-CoV-2 in Ecuador. Sequences generated for this study in 504

black. Variants of concern or of interest are coloured. The time of SARS-CoV-2 introduction is
shown in an orange square at the root of the tree. (B) Number of distinct Pango lineages in time.
Gray zone represents 95% confidence intervals. (C) Pearson correlation test of stringency index
versus number of lineages per month. Gray zone represents 95% confidence intervals. (D)
Spatiotemporal reconstruction of the spread of SARS-CoV-2 in Ecuador during establishment of
non-pharmaceutical interventions (NPIs). NPI implementation time as in (D). (E) Density
estimations of SARS-CoV-2 transitions.